Dr. Brian Courtney and Dr. Aman Thind came together in 2007 to build the foundation for a medical device company.

Valued Partnerships

Brian and Aman found out very early in their partnership that they could work well together and complemented each other’s abilities.

They were good at identifying solutions to complex problems with true clinical impact. Brian and Aman also realized the importance of partnerships clinically, academically as well as with government and industry. With this, they decided to build a company together that would build on these partnerships and allow for development of critically important medical devices in Canada.

Conavi's Story


MedTech Innovator Selects Conavi for 2018 Showcase

Conavi Medical is pleased to announce that we are among the 50 companies selected by MedTech Innovator to participate in the organization’s 2018 showcase. MedTech Innovator is a non-profit organization designed to identify and support innovative early-stage medical device companies. As part of our selection, the Conavi team will attend several MedTech Innovator conferences and events to pursue opportunities for mentorship and support from healthcare industry leaders.


Novasight Hybrid System Receives FDA 510(k) Clearance

Conavi receives 510(k) clearance from the US Food and Drug Administration (FDA) for our Novasight Hybrid System. The system enables simultaneous imaging of coronary arteries with both intravascular ultrasound (IVUS) and Optical Coherence Tomography (OCT). IVUS or OCT are typically used by interventional cardiologists to image coronary anatomy during angioplasty and stenting procedures.

“This is the world’s first intravascular imaging system for clinical use with the capability to acquire both IVUS and OCT images using a single catheter. IVUS and OCT are the two most commonly used intravascular imaging technologies in addition to angiography,” says Dr. Brian Courtney, President and CEO of Conavi. “The Novasight Hybrid System provides the resolution and contrast of OCT with the larger field of view of IVUS, and displays the images in a precisely co-registered fashion.”

Dr. Courtney continues, “This regulatory clearance represents an important milestone for the company as we build a portfolio of image guidance products for cardiovascular procedures. We are delighted to now be able to offer physicians in the USA the opportunity to use the Novasight Hybrid System to obtain intravascular images of coronary arteries as part of their care for patients undergoing interventional procedures.”

Read more


Conavi Enters into Distribution Agreement with China Grand Pharmaceutical and Healthcare

Conavi announces that we have entered into an agreement with an affiliate of China Grand Pharmaceutical and Healthcare Holdings Limited (CG Healthcare) to serve as the exclusive distributor of our Foresight ICE System and Novasight Hybrid System in China, Hong Kong, Taiwan and Macau.

Dr. Brian Courtney, Conavi’s President and Chief Executive Officer, states that “This agreement represents an important commercial milestone for Conavi. China has the second largest volume of cardiovascular interventional procedures in the world and is growing quickly as a result of extensive investments in healthcare infrastructure. We are delighted to have found a partner that shares our vision of bringing the potential benefits of advanced image guidance to a broad range of existing and emerging minimally invasive cardiovascular procedures to patients in China.”

Conavi’s Foresight ICE System has received 510(k) clearances from the United States Food & Drug Administration (FDA) and a Medical Device License from Health Canada and is currently being marketed in North America. The Novasight Hybrid System combines the two most frequently used intravascular imaging technologies, intravascular ultrasound (IVUS) and optical coherence tomography (OCT), into a single catheter and platform. The Novasight Hybrid System has been submitted to the US FDA for 510(k) clearance.

Read more


Foresight ICE™ System Receives FDA Clearance for Expanded Feature Set

Conavi announces 510(k) clearance from the FDA for our Foresight ICE System expanded feature set. The enhancements include Color Doppler, Pulsed Wave Doppler, 2D and 3D measurements, and ECG-gated 3D image acquisition. These enhancements are expected to help electrophysiologists and interventional cardiologists in the US by providing them with the tools to make decisions during minimally invasive cardiovascular procedures.

“This system is the world’s first intracardiac echo system with the capability to acquire 2D and 3D images with a broad field-of-view that includes both side-viewing and forward-looking capabilities. We have now expanded upon this foundation by adding image quality enhancements, features to minimize the effects of cardiac motion and the inclusion of additional imaging modes.” says Dr. Brian Courtney, CEO of Conavi.

The system’s indication for use has been expanded to include the ability to assess physiology with its new Doppler capabilities. Dr. Courtney continues, “The addition of Doppler imaging and flow quantification greatly expands the range of clinical scenarios in which Conavi’s Foresight ICE System can be used. As a result, we are the only provider of rotational ICE that provides Doppler capabilities, and thus benefit from being able to target regions of the cardiac anatomy anywhere around the 360-degree field-of-view of our catheter. The achievement of this 510(k) clearance demonstrates Conavi’s commitment to being a highly responsive source of imaging technologies to physicians performing electrophysiology procedures, structural heart interventions and other cardiovascular procedures that stand to benefit from image guidance.”

Read more


Conavi Partners with Nova Scotia Health Authority and Government of Canada

Conavi announces that we are spearheading a collaborative effort to develop an imaging and tissue cutting probe for guided cardiovascular surgeries. The miniaturized probe leverages ultrasound technology for both imaging and precision cutting, allowing physicians to diagnose and treat serious conditions in a minimally invasive manner.

The Government of Canada is investing $2.6+ million over five years in the Nova Scotia Health Authority (NSHA) to develop the endoscope prototype. Throughout the development, Conavi will lend our medical and technological expertise to assist the NSHA in taking the solution from concept to creation. Upon creation, Conavi will commercialize the solution for cardiovascular surgical applications, allowing patients worldwide to benefit from improved clinical outcomes.

Fellow Toronto-based company Synaptive Medical will also assist in developing the solution and will likewise commercialize the solution for neurological applications.

Read more


Conavi Medical announces Health Canada clearance

Conavi announces that we are now authorized to market and sell the Foresight ICE™ System in Canada. The Foresight ICE System is the first catheter-based ultrasound system capable of providing both 2D and 3D ultrasound images of cardiac anatomy around the circumference of the catheter’s tip.

The authorization comes from Health Canada—Canada’s federal regulator responsible for monitoring and evaluating the safety, effectiveness, and quality of diagnostic and therapeutic medical devices. After evaluating the Foresight ICE System, Health Canada granted a Canadian Medical Device License (MDL)—giving us the clearance needed to market the solution in our home country of Canada.

“Attaining Health Canada approval for our Foresight ICE System represents a key milestone in our mission to provide Canadian physicians with superior visual guidance to achieve improved clinical outcomes” says Murray Maynard, President and CEO of Conavi Medical. “Not only does this approval allow us to begin marketing our technology in Canada, but a device license in our domestic market is key to obtaining regulatory approval in other jurisdictions.”

Read more


Early results from Southlake Regional Health Centre Study

Southlake Regional Health Centre is supporting the first phase of the Foresight ICE Trial using technology initially developed at Sunnybrook Research Institute. This study is looking at the first clinical use and efficacy of 2D forward and 3D intracardiac echocardiography to guide trans-septal punctures during AF ablation procedures. Several patients have already had successful trans-septal puncture supported by the use of the Foresight ICE system.



Foresight ICE System Receives FDA 510(k) clearance

Conavi Medical (formerly Colibri Technologies) announces FDA 510(k) clearance for its first product, the Foresight ICE System for Intracardiac Echocardiography.

The Foresight ICE System is the first catheter- based ultrasound system capable of providing both 2D and 3D ultrasound images of cardiac anatomy around the circumference of the catheter’s tip. The system includes the dual display Conavi Hummingbird imaging console and the Foresight ICE catheter. These products can be used to support a growing number of minimally invasive cardiovascular procedures performed in the US, such as ablations and other procedures that may require access to targeted regions of the heart.

Read more


Conavi partners with OBIO

The Ontario Bioscience Innovation Organization (OBIO) is a not-for-profit, membership-based organization engaged in the development of an integrated health innovation economy for Ontario and one that will become a global leader in providing health technology products and services to the international marketplace.

OBIO’s priorities are to build companies that can stay here and grow and a sustainable industry that will: strengthen Ontario’s economy; commercialize research output; employ the best-educated, most innovative workers in the world and provide cost effective, value-driven healthcare solutions. Conavi Medical was selected as a Capital Access Advisory Program (CAAP) Company in which OBIO operates downstream from existing entrepreneurship programs and targets the critical issue of access to capital at the “Series A” and later stages of venture financing. Led by OBIO and a North American Steering Committee of life science venture capitalists and serial entrepreneurs, CAAP Companies work closely with a team of CAAP Advisors to address specific goals and objectives to position them for financing success. In addition to investor materials preparation and guidance, CAAP Goals include intellectual property, clinical and regulatory, market access other key strategic items to position companies for financing success

Read more


Japan Lifeline and Conavi enter partnership

Conavi and Japan Lifeline (JLL) have signed an agreement to allow JLL to serve as the exclusive distributor of Conavi’s intracardiac echocardiography imaging system in Japan. The companies are working together to obtain the necessary regulatory and reimbursement approval.

Download our Press Release.

Conavi is Built on Leadership


Dr. Brian Courtney

Executive Chairman,


Dr. Aman Thind


Conavi is Built on Leadership

Executive Team

Stefano E. Picone, CPA/CA

Director, Finance

Marc Lukacs, PhD

Director, Technology

Morteza Aval, P. Eng

Director, Software

Althea Lawrence

Director, Quality & Regulatory

Travis More

Director, Human Resources

Board of Directors

Brian Courtney

Executive Chairman

Cameron Piron

President, Synaptive Medical

Kris Shah

President, Baylis Medical

Craig Podolsky

Partner, CPOINT Capital

Joelle Faulkner

President, Area One Farms

Derrick Rolfe

CEO, Bridgebank Capital

Michael K. Wang

Vice President, Grandpharma (China) Co., Ltd.

Robert D. Mitchell

President Emeritus, Endologix